Neutralizing Antibody Response, Safety, and Efficacy of mRNA COVID-19 Vaccines in Pediatric Patients with Inflammatory Bowel Disease: A Prospective Multicenter Case-Control Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Kyung Jae | - |
dc.contributor.author | Choi, So Yoon | - |
dc.contributor.author | Lee, Yoo Min | - |
dc.contributor.author | Kim, Han Wool | - |
dc.date.accessioned | 2022-09-06T06:41:48Z | - |
dc.date.available | 2022-09-06T06:41:48Z | - |
dc.date.issued | 2022-08 | - |
dc.identifier.issn | 2076-393X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/21365 | - |
dc.description.abstract | The vaccination of immunocompromised children against coronavirus disease 2019 is an important public health issue. We evaluated the serological response, safety, and efficacy of the BNT162b2 vaccine in children with and without inflammatory bowel disease (IBD). A prospective, multicenter, case-control study was conducted in a pediatric population, including patients with IBD, aged 12-18 years. Clinical characteristics, safety profile, and serum samples for surrogate virus-neutralizing antibody testing pre- and post-BNT162b2 vaccination were assessed. The breakthrough infection rate during the Omicron outbreak was calculated to evaluate efficacy. Fifteen controls and twenty-three patients with IBD were enrolled. After two vaccine doses, the median level of percentage inhibition was highly increased, without significant differences between the groups (control 96.9 and IBD 96.3). However, it was significantly reduced in IBD patients receiving combination therapy (anti-tumor necrosis factor-alpha + immunomodulators) relative to those in other therapies and controls. Serious adverse events were not observed. The breakthrough infection rate was 42.1%, without statistical differences between the groups. Immunization with BNT162b2 in patients with IBD was comparable with that in healthy adolescents in terms of immunogenicity and safety. Nevertheless, the efficacy of BNT162b2 in preventing infection caused by the Omicron variant in the pediatric population was insufficient. | - |
dc.format.extent | 14 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | - |
dc.title | Neutralizing Antibody Response, Safety, and Efficacy of mRNA COVID-19 Vaccines in Pediatric Patients with Inflammatory Bowel Disease: A Prospective Multicenter Case-Control Study | - |
dc.type | Article | - |
dc.publisher.location | 스위스 | - |
dc.identifier.doi | 10.3390/vaccines10081265 | - |
dc.identifier.scopusid | 2-s2.0-85137390548 | - |
dc.identifier.wosid | 000845116100001 | - |
dc.identifier.bibliographicCitation | Vaccines, v.10, no.8, pp 1 - 14 | - |
dc.citation.title | Vaccines | - |
dc.citation.volume | 10 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 14 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | SARS-COV-2 VACCINATION | - |
dc.subject.keywordPlus | ACTIVITY INDEX | - |
dc.subject.keywordPlus | VALIDATION | - |
dc.subject.keywordPlus | INFLIXIMAB | - |
dc.subject.keywordPlus | CHILDREN | - |
dc.subject.keywordPlus | TRENDS | - |
dc.subject.keywordAuthor | COVID-19 vaccines | - |
dc.subject.keywordAuthor | COVID-19 breakthrough infections | - |
dc.subject.keywordAuthor | inflammatory bowel diseases | - |
dc.subject.keywordAuthor | adolescent | - |
dc.subject.keywordAuthor | pediatric | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.